title: Psoriasis induced by cetuximab: a paradoxical adverse effect.
abstract: Cetuximab, an epidermal growth factor receptor inhibitor, is a chemotherapeutical agent featuring well-known adverse dermatological effects related to tumour-response prognosis. In psoriasis, the epidermal growth factor receptor is overexpressed; hence, the expectation would be that an epidermal growth factor receptor inhibitor could improve psoriatic lesions. We report a case of psoriasis induced by cetuximab, which was a surprising adverse effect.
authors.affiliation: Department of Dermatology, Hospital Universitario Central de Asturias, Oviedo, Spain. albert.mas.vidal@gmail.com
authors.forename: Albert
authors.initials: A
authors.lastname: Mas-Vidal
authors.forename: Pablo
authors.initials: P
authors.lastname: Coto-Segura
authors.forename: Cristina
authors.initials: C
authors.lastname: Galache-Osuna
authors.forename: Jorge
authors.initials: J
authors.lastname: Santos-Juanes
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000068818:Cetuximab; D006801:Humans; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000139:chemically induced*; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068818:Cetuximab